中国循证医学杂志

中国循证医学杂志

ALOX5AP 基因 SG13S114 和 SG13S32 位点多态性与中国人缺血性脑卒中关系的Meta 分析

查看全文

目的 系统评价 ALOX5AP 基因 SG13S114 和 SG13S32 多态性与中国人缺血性脑卒中的相关性。 方法 计算机检索 Web of Science、EMbase、PubMed、CNKI、CBM 和 WanFang Data 数据库,搜集 ALOX5AP 基因 SG13S114 和 SG13S32 多态性与中国人缺血性脑卒中相关的病例对照研究,检索时限均从建库至 2017 年 2 月。由 2 名研究者独立筛选文献、资料提取,并评价纳入研究的偏倚风险后,采用 Stata 12.0 进行 Meta 分析。 结果 共纳入 20 个研究。Meta 分析结果显示:ALOX5AP 基因 SG13S114 多态性与中国人缺血性脑卒中发病风险增加相关[A vs. T:OR=1.12,95%CI(1.00,1.27),P=0.05;TA+AA vs. TT:OR=1.14,95%CI(1.01,1.28),P=0.04;AA vs. TT:OR=1.33,95%CI(1.07,1.65),P=0.012]。此外在五种基因模型中,均未发现 SG13S32 多态性与缺血性脑卒中存在关联。 结论 ALOX5AP 基因 SG13S114 多态性与中国人缺血性脑卒中有关,A 等位基因是其潜在危险因素。而本研究尚未发现 SG13S32 多态性与中国人缺血性脑卒中之间的关联。

Objective To investigate the relationship between SG13S114 and SG13S32 polymorphisms in ALOX5AP gene and risk of ischemic stroke among Chinese population. Methods We conducted a systematic search in Web of Science, EMbase, PubMed, CNKI, CBM and WanFang Data to collect case-control studies about the association between SG13S114 and SG13S32 polymorphisms of ALOX5AP and risk of ischemic stroke from inception to February 2017. Two researchers independently screened literature, extracted data and assessed the risk of bias of included studies. Then meta-analysis was performed by Stata 12.0 software. Results A total of 20 studies were included. The results of meta-analysis showed that SG13S114 polymorphism in ALOX5AP gene was associated with the risk of ischemic stroke in Chinese (A vs. T: OR=1.12, 95%CI 1.00 to 1.27, P=0.05; TA+AA vs. TT: OR=1.14, 95%CI 1.01 to 1.28, P=0.04; AA vs. TT: OR=1.33, 95%CI 1.07 to 1.65, P=0.012). However, no significant associations between SG13S32 polymorphism and ischemic stroke were observed under all five genetic models. Conclusion SG13S114 A allele of ALOX5AP may be a risk factor for ischemic stroke in Chinese.

关键词: ALOX5AP; 多态性; 缺血性脑卒中; Meta 分析; 病例对照研究

Key words: ALOX5AP; Ischemic stroke; Polymorphism; Meta-analysis; Case-control study

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Wu X, Zhu B, Fu L, et al. Prevalence, incidence, and mortality of stroke in the Chinese island populations: a systematic review. PLoS One, 2013, 8(11): e78629.
2. Wang W, Jiang B, Sun H, et al. Prevalence, incidence and mortality of stroke in China: results from a nationwide population-based survey of 480687 adults. Circulation, 2017, 135(8): 759-771.
3. Ke X, Wu X, Guo H, et al. Association of ALOX5AP rs10507391/SG13S114A>T polymorphism with cerebral infarction in the Chinese population: a meta-analysis study. Int J Neurosci, 2015, 125(10): 726-732.
4. Flossmann E, Schulz UG, Rothwell PM, et al. Systematic review of methods and results of studies of the genentic epidemiology of ischemic stroke. Stroke, 2004, 35(1): 212-227.
5. Linsel-Nitschke P, Götz A, Medack A, et al. Genetic variation in the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) is associated with myocardial infarction in the German population. Clin Sci, 2008, 115(10): 309-315.
6. Samuelsson B, Dahlen SE, Lindgren JA, et al. Leukotrienes and lipoxins: Structures, biosynthesis, and biological effects. Science, 1987, 237(4819): 1171-1176.
7. Samuelsson B. Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science, 1983, 220(4597): 568-575.
8. Domingues-Montanari S, Fernandez-Cadenas I, del Rio-Espinola A, et al. Association of a genetic variant in the ALOX5AP with higher risk of ischemic stroke: a case control, meta-analysis and functional study. Cerebrovasc Dis, 2010, 29(6): 528-537.
9. Zintzaras E, Rodopoulou P, Sakellaridis N. Variants of the arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene and risk of stroke: a huge gene-disease association review and meta-analysis. Am J Epidemiol, 2009, 169(5): 523-532.
10. Ye F, Liu NN, Zheng YQ, et al. Three polymorphisms of ALOX5AP and risk of ischemic stroke in Chinese: evidence from a meta-analysis. J Neurol Sci, 2014, 336(1-2): 93-98.
11. Wang G, Liu R, Zhang J. The arachidonate 5-lipoxygenase-activating protein (ALOX5AP) gene SG13S114 polymorphism and ischemic stroke in Chinese population: a meta-analysis. Gene, 2014, 533(2): 461-468.
12. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
13. Yang Y, Zhang D, Feng N, et al. Increased intake of vegetables, but not fruit, reduces risk for hepatocellular carcinoma: a meta-analysis. Gastroenterology, 2014, 147(5): 1031-1042.
14. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 50(4): 1088-1101.
15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ, 1997, 315(7109): 629-634.
16. 邵敏洁, 易兴阳, 池丽芬. 浙江南部地区人群 5-脂氧合酶激活蛋白和磷酸二酯酶 4D 基因突变与缺血性脑卒中的研究. 中华老年心脑血管病杂志, 2013, 15(6): 592-595.
17. 马建华. PDE4D、ALOX5AP 基因单核苷酸多态性与新疆维吾尔族、汉族脑梗死的相关性研究. 乌鲁木齐: 新疆医科大学, 2013.
18. 王剑南, 杨兆宁, 隋强. 5-脂氧合酶激活蛋白及磷酸二酯酶 4D 基因多态性与脑梗死易患性的分子流行病学研究. 蚌埠医学院学报, 2015, 40(10): 1338-1340.
19. 吴海容. ALOX5AP 基因多态性与吸烟的交互作用对缺血性脑卒中的影响. 青岛: 青岛大学, 2013.
20. 何颖蕾, 朱敏, 金笑平, 等. ALOX5AP 基因 SG13S114A/T 多态性与动脉粥样硬化性脑梗死的关系. 浙江大学学报, 2009, 38(6): 630-633.
21. 孙蕾, 李聪, 宋博, 等. ALOX5AP 基因多态性与缺血性脑卒中的相关性. 青岛大学医学院学报, 2012, 48(3): 207-210.
22. 徐佳亮. ALOX5AP 基因和 IL-1A 基因多态性与缺血性卒中的相关性. 沈阳: 中国医科大学, 2009.
23. 姚倩倩, 周畅, 刘丽君, 等. ALOX5AP 基因多态性与动脉粥样硬化性脑梗死相关性. 青岛大学医学院学报, 2013, 49(6): 471-475.
24. 高志嵩, 杜秦川. 缺血性脑卒中 ALOX5AP 基因 SG13S114T/A 和 SG13S89G/A 多态性研究. 宁夏医学杂志, 2008, 30(5): 388-390.
25. 廖断修, 易兴阳, 张标, 等. ALOX5AP 和 CYP3A5 基因多态性与缺血性脑卒中后血栓事件的相关性. 西部医学, 2016, 28(6): 823-828.
26. 池万章, 易兴阳, 黄雪融, 等. ALOX5AP 基因 SG13S114A/T 和 COX-2 基因 765G/C 交互作用增加脑梗死的易感性. 实用医学杂志, 2014, 30(21): 3422-3425.
27. 冯学问, 吴伟林, 陈春友, 等. 5-脂氧合酶激活蛋白基因多态性与脑梗死易患性的临床研究. 中国医师杂志, 2016, 18(2): 212-215.
28. 高卓, 田国萍. 沈阳地区汉族人群脑梗死患者 ALOX5AP 基因 SNP 分析. 中风与神经疾病杂志, 2010, 27(11): 1022-1026.
29. Zhang WL, Yang XM, Shi J, et al. Polymorphism of SG13S114T/A in the ALOX5AP gene and the risk for stroke in a large Chinese cohort. Acta Genetica Sinica, 2006, 33(8): 678-684.
30. Xu C, Qiang L, Limei C, et al. Correlation between cerebral infarction and ALOX5AP gene expression. Cell Biochem Biophys, 2013, 67(3): 899-904.
31. Yang D, He Y, Li M, et al. A novel risk haplotype of ALOX5AP gene is associated with ischemic stroke in Chinese Han population. J Mol Neurosci, 2014, 53(3): 493-499.
32. Qu Z, Su F, Zhu Y, et al. A tagging ALOX5AP polymorphism and risk of ischemic stroke in a northeastern Chinese Han population. Int J Clin Exp Med, 2015, 8(11): 21343-21350.
33. 刘梦. 新疆维吾尔族缺血性脑卒中与 5-脂氧合酶激活蛋白基因 SG13S32 位点多态性的相关性研究. 乌鲁木齐: 新疆医科大学, 2015.
34. 李海先, 吴海容, 李建业, 等. ALOX5AP 基因多态性及肥胖与缺血性脑卒中相关性. 青岛大学医学院学报, 2013, 49(4): 319-325.
35. 池丽芬, 易兴阳, 邵敏洁, 等. 5-脂氧合酶激活蛋白基因多态性与细胞色素 P450 酶 3A5 基因多态联合交互作用显著增加脑梗死风险. 中华神经科杂志, 2013, 46(8): 536-540.
36. The secondery prevention guidelines for ischemic stroke and transient ischemic attack in China. Chin J Neurol 2010; 43(2): 154-160.
37. He G, Ye S, Hui J, et al. Interrelationships between ALOX5AP polymorphisms, serum leukotriene B4 level and risk of acute coronary syndrome. PLoS One, 2014, 9(9): e106596.
38. Mehrabian M, Allayee H, Wong J, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res, 2002, 91(2): 120-126.
39. Spanbroek R, Grabner R, Lotzer K, et al. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci USA, 2003, 100(3): 1238-1243.
40. Dwyer JH, Allayee H, Dwyer KM, et al. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. New Engl J Med, 2004, 350(1): 29-37.
41. Aiello RJ, Bourassa PA, Lindsey S, et al. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol, 2002, 22(3): 443-449.
42. Ghazalpour A, Wang X, Lusis AJ, et al. Complex inheritance of the 5-lipoxygenase locus influencing atherosclerosis in mice. Genetics, 2006, 173(2): 943-951.
43. Chen Z, Zheng J, Liu W, et al. The SG13S114 polymorphism of the ALOX5AP gene is associated with ischemic stroke in Europeans: ameta-analysisof8062subjects. Neurol Sci, 2017, 38(4): 579-587.